| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer |
| Creator | Saadoun et al. |
| Author | H. Saadoun |
| Author | P. J. Lamy |
| Author | S. Thezenas |
| Author | S. Pouderoux |
| Author | F. Bibeau |
| Author | F. Montels |
| Author | G. Romieu |
| Author | P. E. Colombo |
| Author | M. Gutowski |
| Author | W. Jacot |
| Abstract | AIMS: Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer. PATIENTS & METHODS: This monocentric retrospective study included 652 patients who had curative surgery between 2006 and 2011 and adjuvant treatment decision-making, taking into account uPA/PAI-1 tumor levels. RESULTS: uPA and PAI-1 levels were associated with classical clinicopathological parameters and adjuvant chemotherapy decision, but not with peritumoral vascular invasion (PVI; also known as peritumoral vascular emboli). HER2 overexpression, PVI and uPA/PAI-1 levels were not significantly associated with relapse-free survival in univariate analysis. In multivariate analysis, T stage, N stage and progesterone receptors were the only independent relapse-free survival predictive factors. CONCLUSION: The absence of an association between uPA/PAI-1 and PVI allows their concomitant consideration in adjuvant treatment discussion. The overall good prognosis of patients with high uPA/PAI-1 levels might be linked to the uPA/PAI-1 predictive value and the inclusion of these parameters in adjuvant guidelines. |
| Publication | Future Oncol |
| Volume | 10 |
| Pages | 195-209 |
| Date | Feb 2014 |
| Journal Abbr | Future oncology |
| DOI | 10.2217/fon.13.177 |
| ISSN | 1744-8301 (Electronic) 1479-6694 (Linking) |
| Tags | Adult, Aged, Aged, 80 and over, Breast Neoplasms/drug therapy/*metabolism/*mortality/pathology, Chemotherapy, Adjuvant, clinic, Decision Making, Female, Humans, Middle Aged, Neoplasm Staging, Plasminogen Activator Inhibitor 1/*metabolism, Prognosis, Prospective Studies, stan, Urokinase-Type Plasminogen Activator/*metabolism |
| Date Added | 2018/11/14 - 15:25:02 |
| Date Modified | 2019/05/14 - 20:19:25 |
| Notes and Attachments | (Note) (Note) 24490606 (Attachment) |
Institut de Recherche en Cancérologie de
